Treatment

CA-4948 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
This study is testing a new medicine called CA-4948 for people with acute myeloid leukaemia (AML) or certain types of myelodysplastic syndrome (MDS). It aims to see if the medicine is safe and helps improve their condition.
For: Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).
Germany · Spain · France